Celldex Therapeutics (CLDX) Posts Narrower than Expected Q2 Loss of 27c/Sh.
Tweet
Share
E-mailGet Alerts CLDX Hot Sheet
Join SI Premium – FREE
Celldex Therapeutics (NASDAQ: CLDX) reported Q2 EPS of ($0.27), $0.02 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $1.95 million versus the consensus estimate of $2.43 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gilead Sciences (GILD) Misses Q1 EPS by 288c
- Mohawk Industries (MHK) Tops Q1 EPS by 19c
- USCB Financial Holdings, Inc. (USCB) Tops Q1 EPS by 2c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
